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Background: Sarcoidosis is a systemic disease of unknown etiology characterized histologically by the observation
of non-caseating granulomas and several immunological abnormalities. Sarcoidosis is a multi-organ disorder which
involves formation of granulomas in many tissues including the lungs (pulmonary) and others such as skin, bone,
heart (extra pulmonary). Associations between human leukocyte antigens (HLA), the encoded cell surface receptor
(HLA-DR) and sarcoidosis have been reported in several studies. Several HLA-DR alleles have been described as
potential risk factors for sarcoidosis in distinct ethnic groups however evidence for a relationship between HLA-DR
alleles and pulmonary and extra-pulmonary sarcoidosis (EPS) is still scarce. Although the etiology of the disease remains
unclear, infectious and environmental factors have been postulated. Inflammatory cytokines and chemokines may play
important roles in the pathogenesis of sarcoidosis and serum free light chain (FLC) numbers have been implicated in
several immunologic disorders.
Purpose of the study: The aim of the present study was to investigate HLA associations with serum cytokines and
FLC in Iranian patients with pulmonary (n = 86) and EPS (n = 46).
Results: We found that among the 16 HLA DRB alleles only *7 and *12 were different in sarcoidosis patients. The levels
of TNF-α and IL-8 in pulmonary sarcoidosis patients were higher than in EPS (P < 0.05) whereas the levels of FLC
subunits in EPS were higher than in pulmonary sarcoidosis.
Conclusion: This data may suggests a link between HLA-DRB *12 and sarcoidosis in Iranian population.
Keywords: Sarcoidosis, HLA-DR, TNF-α, IL-8Introduction
Sarcoidosis (MIM 181000) is a systemic granulomatous
disease that was originally described over 100 years ago
[1]. Although any organ system can be involved, pulmon-
ary involvement occurs in about 90% of cases although
skin, eye, cardiac, liver and neurologic manifestations are
not uncommon. The disorder has been described in all
races and in every continent except Antarctica [2]. While
many cases may undergo spontaneous regression, one-
third of cases are persistent and require therapy. An* Correspondence: Dr.abedini110@gmail.com
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unless otherwise stated.infectious agent has been suspected as the cause of this
disorder but a non-specific etiology has also been identi-
fied [1,3].
The inflammatory response in sarcoidosis is character-
ized by the accumulation of CD4 T cells at the sites of
disease activity [4]. A Th1 type response has been sus-
pected because of the granulomatous response and the
observation of increased levels of IL-2 and IFN gamma
in the disease [5]. These T cells expressed oligoclonal T
cell receptors consistent with a response to an environ-
mental antigen [6]. These findings strongly supported an
excessive inflammatory reaction or hypersensitivity to
some innocuous agent. The utility of corticosteroids and
other anti-inflammatory drugs in the treatment of this
disorder also support this concept.This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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Table 1 Characteristics of the study population
Organ % (number)
Pulmonary involvement 63 (86)
Extrapulmonary involvement 40 (46)
Skin 30 (34)
Endocrine 9,3 (8)
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ported by studies demonstrating familial clustering [7].
First-degree relatives have a higher prevalence of disease
and familial clustering has been observed in different
populations but most noticeably in African Americans
[8]. Polymorphisms in a number of candidate genes have
been associated with sarcoidosis [9-14].
The clinical presentation of sarcoidosis depends on
epidemiological factors such as age, gender and race; the
duration of the disease and the anatomical sites involved
[15-18]. Although the lungs are involved in most pa-
tients with sarcoidosis, recognition of extra-pulmonary
sarcoidosis (EPS) requires awareness of the organs most
commonly affected, such as the skin and the eyes, and
vigilance for the most dangerous manifestations, such as
cardiac and neurologic involvement. EPS may be life-
threatening and may also affect the therapeutic approach
taken [19].
There is evidence that patients with pulmonary plus
EPS have greater severity of symptoms, restrictions in
daily activities and quality of life and impairment of
health status comparing to the patients with isolated
pulmonary sarcoidosis [20]. However, there are limited
clinical and laboratory parameters that differentiate
patients with pulmonary sarcoidosis alone from those
patients with accompanying EPS.
Cytokines have been implicated in the pathogenesis
of sarcoidosis for many years. In particular, the role of
IL-8 and TNF-α have been frequently studied [21-25].
Granulomas in the skin and lungs have recently been
described as a source of nuclear IL-33 expression and
its expression was strongly correlated with the pres-
ence of systemic disease [26]. The data indicated that
the local inflammatory milieu within each sarcoidal
granuloma is critical for IL-33 expression and that IL-33
expression represents a novel biomarker for systemic in-
volvement of the disease [26].
Serological and molecular analyses of HLA molecules
have also been investigated in sarcoidosis. Unfortunately,
because of the limitations of study design and tech-
niques used to identify HLA molecules (low resolution
molecular typing) it has not been possible to reach a
consensus on the importance of HLA molecules in sar-
coidosis [27]. Currently, there is no information on
organ involvement and frequency of EPS involvement in
sarcoidosis patients from Middle East.
Immunoglobulin free light chains (FLC) can exert
various biological functions: enzymatic activity, binding
to intracellular and extracellular proteins and cellular
interactions [28]. Different inflammatory disorders and
autoimmune diseases are accompanied by elevated FLC
levels in different body fluids [29-34] and the increased
FLC concentrations correlate with relapses of disease and
enhanced activity of the immune system [35-39]. Thus, incurrent study we aimed to investigate whether patients
with pulmonary sarcoidosis differ from those with EPS in
routinely assessed clinical and laboratory data including




Sarcoidosis patients (n =86) were recruited from Sarcoid-
osis clinic center from Massih Daneshvari Hospital be-
tween January 2012 and August 2014, Tehran-Iran. All
patients met the diagnostic criteria for sarcoidosis estab-
lished by the American Thoracic Society consensus panel
[40]. The inclusion criteria consisted of clinical and patho-
logical data and patients with a differential diagnosis were
excluded.
Specific phenotypes of sarcoidosis were defined accord-
ing to the ACCESS group [41]. A summary of the various
extra-pulmonary sites in the clinical cohort is shown in
Tables 1 and 2. Exclusion criteria were individuals with
fungal disease active tuberculosis or who were taking anti-
tuberculosis therapy. Pathology slides were reviewed by a
trained pathologist at each clinical center and the medical
records, chest radiographs and study tests were reviewed
by the principal investigator at each clinical center. An
interviewer-administered questionnaire was also under-
taken by each participant.
Controls
95 controls were recruited as described previously [42]
by random digit dialing (RDD) methods from the same
geographic region as the clinical cases. Controls were
matched to cases on the basis of age (within 5 years),
gender and self-reported race and ethnicity. Controls
were excluded if they reported a history of sarcoidosis or





Number of subjects 86 46 95
Age (mean ± SD) years 39.4 ± 8.8 38.96 ± 9.4 37.7 ± 9.3
Sex
Female 58.8 26.3 55
Male 27.2 20.7 45
Radiologic stage
I
II 2 4 N/A
III 66 19 N/A
IV 18 22 N/A
Current treatment
Steroid (number) 65 32 N/A
Methotrexate (number) 21 14 N/A
CRP (ng/ml) 13.3 ± 14.6 10.1 ± 3 N/A
Hypercalcemia (number) 46 13 N/A
Anemia (number) 21 3 N/A
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sarcoidosis uncertain (e.g. granulomatous hepatitis or
idiopathic uveitis). This study was approved by the
Ethics Committee of Massih Daneshvari Hospital,
Medical College of Shahid Beheshti University and the
Institutional Review Board of National Research Institute
Tuberculosis and Lung Diseases (NRITLD) Medical Cen-
ter and was in compliance with the national legislation
and Declaration of Helsinki guidelines.
DNA preparation
Heparinized blood was collected from each case and
control at the time of the interview and was sent by
overnight courier to the DNA core laboratory for DNA
isolation and purification. High molecular weight DNA
was isolated from non-coagulated blood by detergent
lysis and organic extraction. Purified DNA samples were
diluted to a standard concentration (1 μg/ml) in 10
mMTris, 5 mM EDTA buffer and being frozen at −70°C
until analysed. DNA integrity and concentrations were
monitored using agarose gel electrophoresis and eth-
idium bromide staining.
Determination of HLA-DRB alleles
Determination of HLA-DR B1 subtypes was performed
using single specific primer-polymerase chain reaction
(SSP-PCR) methods (Texas BioGene, USA).The PCR
products were loaded onto a 0.5% agarose gel and the
expression of various alleles was visualized by Gel DOC
(Bio-RAD, USA). HLA-DR subtypes were calculatedaccording to the manufacturer’s instructions. Only primers
that completely matched the target sequences result in
amplified products under the controlled PCR conditions
and the presence of an amplified DNA fragment is a posi-
tive indication of the existence of an allele-specific sequence
in the genomic DNA.
Quantification of serum cytokines
IL-8 concentrations were quantified by ELISA (BD Bio-
sciences Pharmingen, Breda, The Netherlands) according
to the manufacturer’s instructions. Serum levels of
TNF-α, IL-6 and IL-1β were also measured by ELISA
kits (Invitrogen, USA) according to the manufacturer’s
instructions.
Measurement of FLC in serum
Total lambda (λ) and kappa (κ) FLC concentrations were
determined in all sera using an ELISA adapted from Abe
et al. as described previously [43,44]. In brief, plates
were coated o/n with goat anti-mouse IgG (M4280;
Sigma, Zwijndrecht, The Netherlands) at 4°C, blocked (1
h; RT) before incubation with mouse anti-human κ or λ
Ig-FLC MAb’s (obtained from Dr. A. Solomon, Tennes-
see, USA). After incubation with different dilutions of
samples and standards (The Binding Site, Birmingham,
UK), plates were incubated with HRP-labeled goat F(ab’)
2-anti-human λ and κ light chain antibodies (AHI1804
andAHI1904, respectively; Biosource, Life Technologies
Europe, Bleiswijk, The Netherlands). TMB was used as
substrate. At least three data points within the linear
range of the standard curve were used per sample to es-
timate the FLC concentration.
Statistical analysis
All conditions were performed in triplicate, and all ex-
periments were repeated up to five times. Results are
presented as mean ± S.E.M. Data were compared using
the unpaired 2-tailed, student’s t-test using GraphPad
Prism (version 2.01). Results were considered statistically
significant when p < 0.05.
Results
Analysis of the HLADR *B1-16 alleles in the study
population
To determine whether there were different allelic distri-
butions in sarcoidosis patients and their matched con-
trols, a global test was performed for each allele group
of the 16 DRB *1-16 alleles detected. A representative
gel of the results is shown in Figure 1. The data was
quantified and allelic frequencies are given in Tables 3
and 4. The HLA-DRB1 *7 allele was significantly differ-
ent between pulmonary (17.7%) and EPS subjects (4.1%,
p < 0.05) (Table 3). In addition there was a significant
difference in the frequency of the HLA-DRB1 *12 allele
Figure 1 Representative gel electrophoresis of PCR products. Detection of allele-specific amplified bands in 0.5% agarose gel by single
specific primer-polymerase chain reaction (SSP-PCR).The gel is representative of the gel analysis of all DNA samples. Cont = control subject,
EPS = extra-pulmonary sarcoidosis patient and PS = pulmonary sarcoidosis patient. The product size in bp refers to the amplification of a selective
allele in that sample. The internal control represents a conserved region of the house keeping gene (provided in kit) and serves as an indication
of the integrity of PCR reaction.
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(Table 3) and this allele was also identified as a risk factor
for sarcoidosis. The distributions of the HLA-DRB1 alleles
were significantly different between the pulmonary sar-
coidosis patients and the EPS patients (P < 0.001, Table 4).
Levels of IL-8, IL-6and IL-1β in serum of pulmonary and
extra-pulmonary sarcoidosis
The serum levels of IL-8 were significantly increased in
both pulmonary and EPS patients compared with con-
trol subjects (Figure 2, upper panel). There was no sig-
nificant difference between the two sarcoidosis groups
however. The serum levels of IL-6 and IL-1β were not
significantly different between patients with pulmonary
sarcoidosis or EPS or between healthy controls (data not
shown).
Levels of TNF-α in pulmonary higher than extrapulmonary
sarcoidosis
Serum TNF-α levels in pulmonary sarcoidosis patients
were significantly increased compared with control sub-
jects, but no increase was observed in patients with EPS
(Figure 2, lower panel).Table 3 Frequency of HLA-DRB1 in control and sarcoidosis
patients
DR B1* % patients (n = 86) % controls (n = 95) P-value
*01 6.1% 10.4% 0.54
*03 18.4% 14.6% 0.55
*04 10.2% 18.4% 0.18
*07 4.1% 17.7% 0.02
*08 —————— 5.2% 0.16
*09 —————— 1% 1.0
*10 12.2% 5.2% 0.18
*11 36.6% 36.7% 0.87
*12 8.2% 1% 0.04
*13 22.4% 22.9% 0.95
*14 20.2% 12.5% 0.21
*15 32.7% 18.8% 0.06
*16 8.2% 14.6% 0.27Free light chain levels in the serum of pulmonary
sarcoidosis and EPS patients
There was a significant increase in serum κ (Figure 3,
right panel) and λ (Figure 3, left panel) FLC in patients
with EPS compared with control patients. There was no
increase in either κ or λ FLC levels in patients with pul-
monary sarcoidosis as compared to control subjects. The
increase in λ FLC in EPS was also significantly greater
than that in pulmonary sarcoidosis patients.
Discussion
In this study we investigated whether HLA-DRB * sub-
typing could distinguish between sarcoidosis patients with
pulmonary or extra-pulmonary involvement. We found
that among the 16 HLA DRB alleles only *7 and *12 were
different between sarcoidosis patients and controls with
*12 being identified as a risk factor for sarcoidosis [45].
This study shows also a significant difference between the
overall distribution of the HLA-DRB1 alleles between pul-
monary sarcoidosis patients and patients with EPS. We
further demonstrated increased levels of serum TNF-α
and IL-8 in pulmonary sarcoidosis patients, while TNF-α




























































Figure 2 Serum IL-8 and TNF-α levels in sarcoidosis patients.
Serum TNF-αandIL-L8 levels were measured in patients with
pulmonary or extra-pulmonary sarcoidosis. Control subjects were
age-matched with a negative PPD (purified protein derivative) test
and lower angiotensin-converting enzyme (ACE) levels. Data are
presented as mean ± SEM (n = 30) in each group except for controls
where n = 20). *p ≤ 0.05, **p ≤ 0.01 and ***p ≤ 0.01 compared
with control.
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coidosis. This is the first report showing different expres-
sion of HLA-DRB sub-types in pulmonary and EPS. The
differential presence of pro-inflammatory markers such as
TNF-α, IL-8, and FLCs may point to a different pathology
in the two sarcoidosis subgroups.
Among the alleles tested, only the expression of the
*07 and *12 were significantly altered in sarcoidosis with
the frequency of *07 being decreased whereas that of *12
being increased compared with control subjects. It has
previously been reported that the presence of the HLA-
DR B *7 allele is related to a good disease prognosis
[46,47]. Indeed, our patients with this genotype had
good response to treatment. In contrast, in Swedish sar-
coidosis patients the levels of DHL-DR *7 are increased[48]. The frequency of HLA-DR B*012 expression has
been extensively reviewed [49] and the HLA DR-B*12
frequency is similar in our population as in three other
populations from UK, Holland and Japan.
Variations in HLA-DRs associations have also been
reported in sarcoidosis patients across different ethnic
groups. For example, although the frequency of HLA-
DRw52 was significantly greater in Japanese sarcoidosis
patients compared to control groups there was no signifi-
cant association with HLA-B antigens [50]. In addition, an
association between sarcoidosis and HLA-DR5 has been
reported in a German cohort of sarcoidosis patients [51].
This emphasizes that there may be ethnic differences in
the expression of these specific alleles in sarcoidosis pa-
tients and that there is a need to further analyze other
HLA class I and II subtypes in Iranian sarcoidosis patients
in future studies.
We also report enhanced levels of serum IL-8 in both
pulmonary sarcoidosis and EPS patients. To our know-
ledge there has only been one previous report showing
elevated IL-8 levels in sarcoidosis [52]. Car and col-
leagues showed that IL-8 levels were significantly in-
creased in bronchoalveolar fluid (BAL) of patients with
sarcoidosis [53]. IL-8 is rapidly produced by different cell
types upon exposure to inflammatory stimuli such as
TNF-α and LPS and is considered as one of the most
potent neutrophil chemoattractants in human tissue
[54-57]. Recent evidence using blood transcriptomic
analysis [58] indicates that neutrophilia is present in sar-
coidosis patients as well as in other interferon- and
immune-related diseases linked to activation of pattern
recognition receptors and to anti-bacterial and -viral de-
fenses. The clinical importance of the increased levels of
IL-8 in serum and BAL needs further testing.
In addition, serum levels of TNF-α were increased in
patients with pulmonary sarcoidosis but not in those
with EPS. TNF-α is a pro-inflammatory cytokine previ-
ously shown to play a critical role in the pathogenesis of
Th1 responses and to be elevated in sarcoidosis patients
[58]. TNF-α plays a significant role in antigen-stimulated,
cell-mediated immune responses and in the development
of non-caseating granulomas in a variety of diseases [59].
In sarcoidosis, alveolar macrophage-derived TNF-α partic-
ipates in the induction and maintenance of granulomas
[60] and high levels of TNF-α released from alveolar mac-
rophages seem to correlate with disease progression [61].
In addition, BAL levels of TNF-α and IL-6 are significantly
higher in pulmonary sarcoidosis patients compared with
control subjects [62]. Thus, we were able to recapitulate
the BAL findings in relation to TNF-α in blood in our
study.
However, the failure to demonstrate increased serum
levels of IL-1β and IL-6 in sarcoidosis requires further
investigation. This may result from the involvement of
Figure 3 The levels of free light chain (FLC) κand λ in serum of sarcoidosis patients. Free light chain concentrations in serum of sarcoidosis
patients. Kappa (κ, right panel) and lambda (λ, left panel) FLC concentrations are significantly highly increased in the serum of extra-pulmonary
sarcoidosis patients compared with patients with pulmonary sarcoidosis and in control subjects. Results are expressed as means ± SEM of results
from 20 control subjects, 30 pulmonary sarcoidosis subjects and 30 extra-pulmonary sarcoidosis patients.
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cytokines and chemokines are all stimulated by the same
stimuli involving NF-κB activation [63]. This may also
explain the differences in TNF-α expression observed
between pulmonary sarcoidosis and EPS.
We also report elevated levels of both κ and λ FLC in
the serum of EPS patients but not patients with pulmon-
ary sarcoidosis. Sarcoidosis is known as a T cell mediated
disease but B-cells may play a role in its pathogenesis
particularly in chronic disease [64,65]. It is possible that
the release of free light chains is from a distinct set of
inflammatory cells in the blood of these patients. A
growing body of evidence suggests that serum FLCs
could be useful biomarkers in several immunological
conditions as they reflect B-cell polyclonal activation in-
cluding active sarcoidosis [65]. Serum FLC levels are also
elevated in lupus [66], rheumatoid arthritis and Sjögren
syndrome [37,45,67] where they are also associated with
the active state of the disease. Serum FLCs have also re-
cently been reported as biomarkers of systemic sclerosis
activity and severity [68,69]. In the current study the ex-
pression of κ and λ FLCs was greater in EPS patients
compared with patients with pulmonary sarcoidosis. The
differential expression of κ and λ FLCs in EPS and
pulmonary sarcoidosis requires confirmation in other
cohorts and its functional importance needs to be fur-
ther established. However, we speculate that B cells may
play a more significant role in EPS compared to pul-
monary sarcoidosis and that these patients may benefit
from B cell-directed therapy.
In conclusion, we report for the first time that HLA
DRB *12 may be indicative of sarcoidosis and that there
is a differential HLA DRB allele usage between patients
with EPS and pulmonary sarcoidosis. There were also dif-
ferences in serum inflammatory markers between these
two groups of sarcoidosis patients with patients with
pulmonary sarcoidosis having greater levels of TNF-α and
IL-8 than EPS and control subjects. Conversely, the ex-
pression of κ and λ FLCs was greater in EPS patients com-
pared with pulmonary sarcoidosis patients. Overall, wereport a link between HLA-DRB sub-types and inflamma-
tion in Iranian patients with sarcoidosis. We suggest that
these novel markers should be readily incorporated into
current laboratory analysis as they are relatively cheap and
rapid, taking less than 48 h, and provide additional param-
eters for the differentiation of subtypes of sarcoidosis.
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